Detection of types of HPV among HIV-infected and HIV-uninfected Kenyan women undergoing cryotherapy or loop electrosurgical excision procedure.
Cryotherapy
Electrosurgery
HIV infections
Kenya
Papillomavirus infections
Uterine cervical dysplasia
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
13
02
2020
revised:
31
05
2020
accepted:
16
07
2020
pubmed:
28
7
2020
medline:
30
12
2020
entrez:
28
7
2020
Statut:
ppublish
Résumé
To assess the baseline types of HPV infection among HIV-positive and HIV-negative women in western Kenya undergoing cryotherapy or loop electrosurgical excision procedure (LEEP) for cervical intraepithelial neoplasia. A prospective observational study was conducted of baseline HPV characteristics of women undergoing visual inspection with acetic acid (VIA) and cryotherapy or LEEP. After a positive VIA in HIV-positive and HIV-negative women, data on demographics, CD4 count, and use of antiretroviral therapy and a cervical swab were collected. HPV typing was performed using the Roche Linear Array. Of 175 participants, 86 (49.1%) were HIV-positive and had a higher prevalence of low-risk HPV types (odds ratio [OR] 5.28, P=0.005) compared with HIV-negative women. The most common high-risk (HR)-HPV types in HIV-positive women were HPV 16 (13.9%) and HPV 18 (11.1%). HIV-positive women requiring LEEP were more likely to have HR-HPV types (OR 6.67, P=0.012) and to be infected with multiple HR-HPV types (OR 7.79, P=0.024) compared to those undergoing cryotherapy. HIV-positive women requiring LEEP versus cryotherapy had a higher prevalence of any HR-HPV type and multiple HR-HPV types. There were no such differences in HPV types identified among HIV-negative women.
Identifiants
pubmed: 32715467
doi: 10.1002/ijgo.13330
pmc: PMC7541596
mid: NIHMS1627809
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
279-286Subventions
Organisme : Providence/Boston CFAR
Organisme : NCI NIH HHS
ID : U54 CA254518
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010050
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA190151
Pays : United States
Organisme : NIH HHS
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States
Informations de copyright
© 2020 International Federation of Gynecology and Obstetrics.
Références
Lancet Infect Dis. 2007 Jul;7(7):453-9
pubmed: 17597569
Virol J. 2018 Mar 27;15(1):54
pubmed: 29587796
BMJ Open. 2018 Jan 27;8(1):e019894
pubmed: 29374678
J Natl Cancer Inst Monogr. 2003;(31):3-13
pubmed: 12807939
Virol J. 2018 Feb 17;15(1):36
pubmed: 29454382
AIDS. 2018 Mar 27;32(6):795-808
pubmed: 29369827
Clin Infect Dis. 2017 May 1;64(9):1228-1235
pubmed: 28199532
AIDS. 2006 Nov 28;20(18):2337-44
pubmed: 17117020
Vaccine. 2012 Nov 20;30 Suppl 5:F168-74
pubmed: 23199960
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
Vaccine. 2012 Nov 20;30 Suppl 5:F12-23
pubmed: 23199955
J Infect Dis. 2003 Aug 15;188(4):555-63
pubmed: 12898443
PLoS One. 2016 Oct 20;11(10):e0163965
pubmed: 27764092
Ann Saudi Med. 2016 Sep-Oct;36(5):313-320
pubmed: 27710981
Br J Cancer. 2012 Oct 23;107(9):1624-30
pubmed: 23033006
J Natl Cancer Inst. 2011 Jun 22;103(12):918-9
pubmed: 21693755
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):886-894
pubmed: 28515108
J Prev Med Hyg. 2017 Dec 30;58(4):E259-E265
pubmed: 29707656
J Acquir Immune Defic Syndr. 2014 May 1;66 Suppl 1:S130-7
pubmed: 24732817
Open Virol J. 2013;7:19-27
pubmed: 23494633
BMC Infect Dis. 2019 Apr 27;19(1):352
pubmed: 31029097
Infect Agent Cancer. 2016 Nov 11;11:56
pubmed: 27843487